Vertex SVP awarded 4,250 performance shares

Vertex Pharmaceuticals executive Kristen Ambrose, SVP & Chief Accounting Officer, reported the acquisition of company stock tied to performance awards.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Kristen Ambrose, SVP & Chief Accounting Officer, reported the acquisition of company stock tied to performance awards. On 01/22/2026, Ambrose acquired 2,950 shares of Vertex common stock at $0 per share from an earned performance stock unit award originally granted on 02/01/2023, increasing direct holdings to 10,795 shares.

On the same date, Ambrose also acquired 1,300 additional shares at $0 per share from a separate performance stock unit award granted on 02/12/2025, bringing direct ownership to 12,095 shares. The filing explains that these are earned performance shares following the compensation committee’s certification of performance-goal attainment on 01/22/2026, with the related shares scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.

Insider Trade Summary

Grant/Award: 4,250 shares

Grant/Award 2 txns

Insider Ambrose Kristen

Role SVP & Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,950	$0.00	$0.00
Grant/Award	Common Stock	1,300	$0.00	$0.00

Holdings After Transaction: Common Stock — 12,095 shares (Direct)

Footnotes (2)

1. F1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
2. F2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VRTX report for Kristen Ambrose?

The filing shows that Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, acquired two blocks of common stock as earned performance shares on 01/22/2026.

How many Vertex (VRTX) shares did Kristen Ambrose acquire in this Form 4?

Kristen Ambrose acquired 2,950 shares of Vertex common stock from a 2023 performance stock unit award and 1,300 shares from a 2025 performance stock unit award, both reported at $0 per share.

What is the source of the shares reported in this VRTX Form 4?

The reported shares are earned performance shares from performance stock unit awards granted on 02/01/2023 and 02/12/2025, which had performance-vesting requirements.

When were the performance goals for the VRTX awards certified?

Vertex’s management development and compensation committee certified the level of performance-goal attainment on 01/22/2026 for both performance stock unit awards.

When will the newly earned VRTX performance shares vest for Kristen Ambrose?

The shares from the 02/01/2023 award will vest on 02/13/2026, and the shares from the 02/12/2025 award will vest in installments beginning on 02/24/2026.

What is Kristen Ambrose’s ownership form for these VRTX shares?

The Form 4 reports that Kristen Ambrose holds the acquired Vertex common stock directly, as indicated by the ownership code D in the table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ambrose Kristen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		2,950(1)	A	$0	10,795	D
Common Stock	01/22/2026		A		1,300(2)	A	$0	12,095	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.